FeedworthyAI
Business & Finance

PharmExec articles

pharmexec.com

PharmExec articles

newsBusiness & Finance

Articles100

<![CDATA[The Road Ahead: Advice for Pharma's Next Board Meeting]]>

<![CDATA[AI at the FDA: Efficiency, Oversight, and Open Questions]]>

<![CDATA[The Impact from Overlaps Between 340B and the IRA]]>

<![CDATA[Pharmaceutical Executive Daily: 2026 Emerging Pharma Leaders Award Winners Announced]]>

<![CDATA[Pharmaceutical Cold-Chain Logistics: Protecting Integrity from End to End (Aug 2026)]]>

<![CDATA[Preventing Product Loss: How to Protect High-Value, Perishable Pharma Freight]]>

<![CDATA[2026 Emerging Pharma Leaders]]>

<![CDATA[Preventing Cardiovascular Disease Through Mission-Driven Leadership]]>

<![CDATA[Making the Smart Career Moves]]>

<![CDATA[Two Decades of Technology Transformation in Pharma]]>

<![CDATA[What C-Suite Readiness Really Requires]]>

<![CDATA[Finding the Universal Truth in a Drug's Story]]>

<![CDATA[Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing ]]>

<![CDATA[Modern Policy Concerns Stemming from 340B]]>

<![CDATA[Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics]]>

<![CDATA[Taking a Hard Look at Pharma's Traditional Margin Model]]>

<![CDATA[The performance gaps most fleet programs can’t see]]>

<![CDATA[Beyond the Segment: How Persona Intelligence Helps Refine HCP Engagement at Scale]]>

<![CDATA[Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for alvelestat ]]>

<![CDATA[The AI Oversight Gap, Siloed Systems, and What a Truly Inspection-Ready Company Looks Like: Q&A with Joseph Morwald]]>

<![CDATA[The Current Status of the 340B Program]]>

<![CDATA[Pharmaceutical Executive Daily: Executive Order Reduces Childhood Vaccine Recommendations]]>

<![CDATA[U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report ]]>

<![CDATA[What 40 Conversations About a Pandemic Taught Me About How Pharma Communicates]]>

<![CDATA[Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report ]]>

<![CDATA[BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies ]]>

<![CDATA[The Science of Targeting Multiple Immune Components in ITP: Q&A with Dr. Srikanth Nagalla]]>

<![CDATA[Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors]]>

<![CDATA[How Companies can be Well-Prepared for Regulatory Inspection]]>

<![CDATA[Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience]]>

<![CDATA[From Diagnosis to Design: How Physician-Scientists Are Building Future-Ready Pharma Organizations]]>

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[Your Product Is Ready. Your Launch Strategy Isn't]]>

<![CDATA[M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo]]>

<![CDATA[Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance]]>

<![CDATA[The Significance of FDA’s First Warning Letter for Inappropriate Use of AI]]>

<![CDATA[Pharmaceutical Executive Daily: Amazon Pharmacy to Offer GLP-1 Delivery Service]]>

<![CDATA[Amazon Pharmacy Launches GLP-1 Delivery Service ]]>

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

<![CDATA[FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma]]>

<![CDATA[FDA's New Frontier: Drug Pricing Enters the Conversation]]>

<![CDATA[Onshoring Commitments and the Public Narrative Behind Them]]>

<![CDATA[Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026]]>

<![CDATA[The Structural Problems Causing the Pharma and Biotech Industries’ Compliance Failures]]>

<![CDATA[The Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Orezeyful]]>

<![CDATA[Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton]]>

<![CDATA[FDA Approves Orezeyful for Narcolepsy Type 1 in Adults ]]>

<![CDATA[Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs]]>

<![CDATA[FDA Approves Moderna's mRNA-Based Flu Vaccine ]]>

<![CDATA[Mergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumors]]>

<![CDATA[Why FDA is Sending an Increased Number of Drug Warning Letters]]>

<![CDATA[Pharmaceutical Executive Daily: Source Denies AstraZeneca-Bristol Myers Merger Talks]]>

<![CDATA[Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition]]>

<![CDATA[Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report ]]>

<![CDATA[CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China]]>

<![CDATA[Pharmaceutical Executive Daily: Pathos AI Enters Two lIcensing Deals]]>

<![CDATA[Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition]]>

<![CDATA[M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Enters Merger Agreement with Lantheus ]]>

<![CDATA[Addressing China’s Rise in Biotech by Removing Barriers: Q&A with John Stanford]]>

<![CDATA[Pharmaceutical Executive Daily: AstraZeneca and Bristol Myers Squibb Held Merger Talks]]>

<![CDATA[Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change]]>

<![CDATA[Sandoz Agrees to $450 Million Settlement With 43 US States Over Generic Drug Antitrust Claims]]>

<![CDATA[Where Tech Meets Touch: Gifthealth's Blueprint for the Prescription Journey]]>

<![CDATA[AstraZeneca and Bristol Myers Squibb Held Merger Talks: Report]]>

<![CDATA[How Regulators and the Industry Can Work Together to Improve the US Pharma Ecosystem ]]>

<![CDATA[Why Real-Time Data Analytics Are Vital for the Next Evolution of Clinical Trials]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data]]>

<![CDATA[FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study ]]>

<![CDATA[Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s ]]>

<![CDATA[Manufacturing on the Move: Tariffs, Reshoring, and the Germany Investigation]]>

<![CDATA[Patient Access, Innovation, and the Global Cost of MFN]]>

<![CDATA[What Steps US Regulators Are Taking to Promote Domestic Investment]]>

<![CDATA[Pharmaceutical Executive Daily: Inizio Engage launches Connected Insights]]>

<![CDATA[Inizio Launches Connected Insights for Global Medical Information ]]>

<![CDATA[The Intelligence Economy: Human-Guided AI for Pharma's Next Era]]>

<![CDATA[M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK ]]>

<![CDATA[DSCSA Compliance Guide: What to do now that enforcement as begun]]>

<![CDATA[Implementing a scalable pharmaceutical serialization system]]>

<![CDATA[What GS1 Certification Means for DSCSA (and why it matters)]]>

<![CDATA[To Aggregate or not to aggregation (It's not really a question)]]>

<![CDATA[DSCSA Serialization Checklist]]>

<![CDATA[GS1-certified traceability for DSCSA-ready supply chains]]>

<![CDATA[When Foreign Investments in Pharma and Biotech Become a National Security Concern]]>

<![CDATA[Addressing Launch Drift to Optimize Product Launches]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Viatris's Gwyn Lo]]>

<![CDATA[What FDA's Peptide Decision Means for the Industry]]>

<![CDATA[FDA Approves Viatris’ Gwyn Lo Contraceptive Patch ]]>

<![CDATA[Replimune Shares Crash Following FDA Review of Melanoma Treatment]]>

<![CDATA[The Experiment Worked, The Knowledge Didn't Survive It]]>

<![CDATA[Closing the GLP-1 Coverage Gap: Q&A with Susan Thomas]]>

<![CDATA[Why Chinese Biotech Licensing Deals Became Attractive to US Investors]]>

<![CDATA[The Ron Lanton Report: The Human Bottleneck ]]>

<![CDATA[Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration]]>

<![CDATA[BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment ]]>

<![CDATA[Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Secures $21 Million Series A ]]>

<![CDATA[How MBA Graduates Can Break into Competitive Industries in 2026: 4 Practical Steps]]>

<![CDATA[Operation Trialblazer and Why Clinical Trials are Leaving the US: Q&A with Richard Graham]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Simtriyo]]>

<![CDATA[FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients ]]>